Clonidine Dosage Recommendations
For adult hypertension, start clonidine at 0.1 mg twice daily (morning and bedtime) and titrate by 0.1 mg/day weekly to a typical maintenance dose of 0.2-0.6 mg/day in divided doses, with elderly patients requiring lower initial doses. 1
Adult Hypertension Dosing
Initial Dosing
- Standard adults: 0.1 mg twice daily (morning and bedtime) 1
- Elderly patients: Lower initial dose of 0.05 mg twice daily 2
- Consider taking the larger portion at bedtime to minimize dry mouth and drowsiness 1
Titration and Maintenance
- Increase by 0.1 mg/day at weekly intervals until blood pressure goal achieved 1
- Typical maintenance range: 0.2-0.6 mg/day in divided doses 1
- Maximum effective dose: 2.4 mg/day (rarely needed) 1
- For twice-daily dosing, administering at 8 AM and 4 PM produces less blood pressure fluctuation than 8 AM and 10 PM 3
Special Populations
- Renal impairment: Start with lower initial dose and monitor carefully; no supplemental dosing needed after hemodialysis 1
- Elderly with diuretic: Can add clonidine 0.1-0.3 mg twice daily to chlorthalidone 25 mg daily for resistant hypertension 2
Pediatric ADHD Dosing
For children 6-17 years with ADHD, use extended-release clonidine starting at 0.1 mg at bedtime, titrating over 3 weeks to target doses of 0.2-0.4 mg/day. 4, 5
Dosing Strategy
- Initial: 0.1 mg at bedtime
- Titration period: 3 weeks of dose escalation 4
- Target doses: 0.2 mg/day or 0.4 mg/day (approximately 0.9 mg/day based on PBPK modeling) 4, 6
- Significant symptom improvement typically seen by week 2 4
Important Considerations
- Extended-release formulations preferred for ADHD 5
- Monitor heart rate and blood pressure before and during treatment 5
- Never discontinue abruptly - taper gradually to avoid rebound hypertension 5, 1
- Most common side effect is mild-to-moderate somnolence 4
Opioid Withdrawal Dosing
For methadone withdrawal, use clonidine at a peak dose of approximately 16 mcg/kg/day (roughly 1.1 mg/day for a 70 kg adult), administered over 10-11 days. 7
Dosing Protocol
- Target dose: 16 mcg/kg/day (mean peak dose from controlled studies) 7
- Duration: 10-11 days typically required 7
- Administer in divided doses every 6-8 hours 8
- Alternative regimen: 0.1-0.2 mg orally every 6 hours 8
Efficacy and Limitations
- 80% of patients successfully completed withdrawal in controlled settings 7
- Most effective for autonomic symptoms (sweating, elevated blood pressure)
- Less effective for: anxiety, restlessness, insomnia, and muscle aching 7
- Monitor standing blood pressure closely as significant reductions occur 7
Critical Safety Warnings
Withdrawal Syndrome
Abrupt discontinuation of clonidine can cause life-threatening hypertensive crisis. 1, 9
- Symptoms include nervousness, agitation, headache, tremor, rapid blood pressure rise, and elevated catecholamines 1
- Risk is higher with: longer duration of use, higher doses, concurrent beta-blocker therapy 1
- Rare but serious complications: hypertensive encephalopathy, stroke, death 1
Discontinuation Protocol
- Always taper over 2-4 days minimum 1
- If on concurrent beta-blocker, discontinue beta-blocker several days before tapering clonidine 1
- Pediatric patients particularly vulnerable due to vomiting illnesses that interrupt dosing 1
- Rebound hypertension can be reversed with oral clonidine or IV phentolamine 1
Cardiovascular Monitoring
- Obtain cardiac history (sudden death, Wolff-Parkinson-White, long QT, hypertrophic cardiomyopathy) before initiating 5
- Monitor heart rate and blood pressure regularly during treatment 5
- Expect mild decreases in both parameters (opposite of stimulants) 5
Context-Specific Considerations
Clonidine is NOT a first-line agent for routine hypertension - the 2017 ACC/AHA guidelines do not recommend it for standard hypertension management [10-11]. It appears only in the context of hypertensive emergencies caused by catecholamine excess (pheochromocytoma, cocaine toxicity, amphetamine overdose, or clonidine withdrawal itself) 12, 11.
For resistant hypertension, the 2025 guidelines recommend spironolactone as the preferred fourth-line agent over clonidine, though clonidine showed some efficacy in one trial 13.